![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- Casadio P, Guasina F, Talamo MR, Paradisi R, Morra C, Magnarelli G, Seracchioli R. 2019. Conservative hysteroscopic treatment of stage I well differentiated endometrial cancer in patients with high surgical risk: a pilot study. Journal of Gynecologic Oncology 30:e62.
- Falcone F, Leone Roberti Maggiore U, Di Donato V, Perrone AM, Frigerio L, Bifulco G, et al. 2020. Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study. Journal of Gynecologic Oncology 31:e74.
- Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. 2012. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology 207:266.e1–12.
- Gunderson CC, Fader AN, Carson KA, Bristow RE. 2012. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecologic Oncology 125:477–482.
- Makris GM, Mene J, Battista MJ, Chrelias G, Sergentanis TN, Psyrri A, Chrelias C. 2018. Endometrial carcinoma with tibial bone metastasis: a case report and literature review. Journal of Obstetrics and Gynaecology 38:1039–1047.
- Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. 2016. Endometrial cancer. Lancet 387:1094–1108.
- Ouldamer L, Bendifallah S, Body G, Touboul C, Graesslin O, Raimond E, et al. 2019. Incidence, patterns and prognosis of first distant recurrence after surgically treated early stage endometrial cancer: results from the multicentre FRANCOGYN study group. European Journal of Surgical Oncology 45:672–678.
- Prat J, Franceschi S, Denny L, Lazcano Ponce E, Stewart BW, Wild CP 2014. Endometrial cancer. In: Stewart BW, Wild CP, editors. World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer. p. 465–481.
- Raffone A, Catena U, Travaglino A, Masciullo V, Spadola S, Della Corte L, et al. 2021. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: a multi-center study. Gynecologic Oncology 161:795–801.
- Raffone A, Travaglino A, Saccone G, Mollo A, De Placido G, Insabato L, Zullo F. 2019. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. Acta Obstetricia et Gynecologica Scandinavica 98:976–987.
- Rodolakis A, Biliatis I, Morice P, Reed N, Mangler M, Kesic V, et al. 2015. European Society of Gynecological Oncology Task Force for Fertility Preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients. International Journal of Gynecological Cancer 25:1258–1265.
- Siegel RL, Miller KD, Fuchs HE, Jemal A. 2021. Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians 71:7–33.
- Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, De Placido G, Zullo F. 2018. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology 231:104–110.
- Trojano G, Olivieri C, Tinelli R, Damiani GR, Pellegrino A, Cicinelli E. 2019. Conservative treatment in early stage endometrial cancer: a review. Acta Biomed 90:405–410.
- Yang B, Xu Y, Zhu Q, Xie L, Shan W, Ning C, et al. 2019. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecologic Oncology 153:55–62.